# The Cooper Companies, Inc. (COO) Stock Report: Analyzing a 23.91% Potential Upside for Investors

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-report-analyzing-a-23-91-potential-upside-for-investors/4121217355
- Published: 2025-09-22T10:33:57+01:00
- Author: Madison Wilson

The Cooper Companies, Inc. (NYSE: COO), a prominent player in the healthcare sector
with a focus on medical instruments and supplies, presents an intriguing opportunity
for investors. With a market capitalization of $13.55 billion, the company operates
through two primary segments: CooperVision, which provides a range of contact lenses,
and CooperSurgical, which focuses on family and women’s health care products. Headquartered
in San Ramon, California, Cooper Companies has established a strong presence across
the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Currently trading at $68.17, the stock is near the lower end of its 52-week range
of $64.32 to $110.34, suggesting potential room for recovery. The company’s forward-
looking valuation metrics, including a forward P/E ratio of 15.48, indicate that
the stock might be undervalued relative to its earnings potential. Despite the absence
of a trailing P/E ratio and PEG ratio, the forward P/E provides a window into future
earnings expectations, potentially appealing for value-conscious investors.

Revenue growth remains steady at 5.70%, reflecting the company’s ability to maintain
momentum in its key markets. Although specific net income figures are not available,
the earnings per share (EPS) of $2.04 combined with a return on equity of 5.01% 
suggest operational efficiency. Moreover, a robust free cash flow of over $276 million
underscores Cooper’s capacity to reinvest in growth initiatives and weather economic
fluctuations.

Analyst sentiment towards Cooper Companies is predominantly positive, with 11 buy
ratings versus 6 hold ratings and no sell ratings. The average target price of $
84.47 implies a compelling potential upside of 23.91% from the current trading price,
reinforcing its attractiveness as a growth candidate. The target price range spans
from $66.00 to $96.00, providing a spectrum of expectations that could cater to 
varying risk appetites.

However, technical indicators paint a cautious picture. The stock’s 50-day moving
average is $70.80, while the 200-day moving average stands at $81.02, suggesting
recent price weakness. The Relative Strength Index (RSI) at 35.39 hints at the stock
being oversold, potentially setting the stage for a rebound. The Moving Average 
Convergence Divergence (MACD) and signal line, both hovering around -1.38 to -1.39,
further emphasize the bearish sentiment in the short term.

One notable aspect of Cooper Companies is its absence of dividend yield, with a 
payout ratio of 0.00%. This signals that all earnings are reinvested back into the
business, a strategy often favored by growth-oriented investors seeking capital 
appreciation over immediate income.

Cooper Companies’ diverse portfolio, spanning vision care and women’s health, positions
it well to leverage demographic trends and healthcare demands. As the global market
for contact lenses and fertility products expands, the company’s dual focus could
drive sustainable growth.

Investors considering Cooper Companies should weigh the potential upside against
the current technical indicators and market conditions. For those willing to navigate
the short-term volatility, the long-term growth prospects and analyst confidence
may offer a rewarding investment opportunity.

Share on: